Jiangsu Jibeier Pharmaceutical Co Ltd688566
▲ PositiveCapitalrelevance
First-half revenue growth and dividend announcement, with core pipeline nearing payoff.
Impact on stocks 1
Others
Jiangsu Jibeier Pharmaceutical Co LtdJibeier disclosed its 2026 semi-annual report on the evening of August 27. In the first half, it achieved operating revenue of 490 million yuan, up 7.61 percent year on year, and plans to pay a cash dividend of 2.60 yuan per 10 shares, totaling about 52.29 million yuan. The company's core product, Likejun tablets, holds an absolute leading position in the white blood cell elevating drug segment, while Niqunluoer tablets, as China's first Class 1 compound antihypertensive new drug, are becoming a second growth driver. In research and development, the antidepressant new drug JJH201501 has completed Phase III clinical trials, and the production license application is progressing in an orderly manner; the anti-tumor drug JJH201601 has completed Phase IIa clinical enrollment and has been approved to conduct a pivotal Phase III study in the third-line biliary tract cancer population. Through its three major business divisions and academic promotion model, the company is expected to open up greater growth potential while maintaining steady operations.
Jiangsu Jibeier Pharmaceutical Co LtdFirst-half revenue growth and dividend announcement, with core pipeline nearing payoff.